Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

121. Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism?

Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? BestBets: Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? Report By: Dr Tom Jaconelli - Registrar in Emergency Medicine Search checked by Dr Steven Crane - Consultant in Emergency Medicine Institution: York (...) District Hospital, York, UK Date Submitted: 26th December 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with signs and symptoms of pulmonary embolism who are deemed low risk] is a [age adjusted D-dimer sensitive enough] compared to a standard D-dimer to [safely exclude pulmonary embolism]? Clinical Scenario A70 year old man presents with pleuritic chest pain. A D-dimer taken at triage is mildly elevated from the standard positive

2015 BestBETS

122. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study (PubMed)

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients.A post hoc

Full Text available with Trip Pro

2015 EvidenceUpdates Controlled trial quality: uncertain

123. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. (PubMed)

Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. Although retrievable inferior vena cava filters are frequently used in addition to anticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is unclear.To evaluate the efficacy and safety of retrievable vena cava filters plus anticoagulation vs anticoagulation alone for preventing pulmonary embolism (...) recurrence in patients presenting with acute pulmonary embolism and a high risk of recurrence.Randomized, open-label, blinded end point trial (PREPIC2) with 6-month follow-up conducted from August 2006 to January 2013. Hospitalized patients with acute, symptomatic pulmonary embolism associated with lower-limb vein thrombosis and at least 1 criterion for severity were assigned to retrievable inferior vena cava filter implantation plus anticoagulation (filter group; n = 200) or anticoagulation alone

Full Text available with Trip Pro

2015 JAMA Controlled trial quality: predicted high

124. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis

Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

125. Pulmonary Embolism (PE): Diagnosis

Pulmonary Embolism (PE): Diagnosis © 2015 Thrombosis Canada Page 1 of 1 PULMONARY EMBOLISM (PE): DIAGNOSIS OBJECTIVE: To provide a diagnostic approach to patients with suspected acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE) is a common disease, affecting approximately 1-2 in 1,000 adults per year. Approximately one third of first VTE presentations are due to PE while the remainder is due to deep vein thrombosis (DVT). The diagnosis of PE has increased significantly (...) such as SPECT V/Q, has high sensitivity and specificity in patients with a normal chest X-ray who do not have significant lung disease. V/Q scanning should be considered in patients with renal insufficiency, contrast allergy and in young patients with a normal chest X-ray. © 2015 Thrombosis Canada Page 3 of 3 FIGURE 1: SUGGESTED DIAGNOSTIC ALGORITHM FOR SUSPECTED PULMONARY EMBOLISM * Consideration for thrombolysis without diagnostic test confirmation should be made if the patient has a high clinical

2015 Thrombosis Interest Group of Canada

126. Predictive value of the heart-type fatty acid-binding protein and the Pulmonary Embolism Severity Index in patients with acute pulmonary embolism in the emergency department (PubMed)

Predictive value of the heart-type fatty acid-binding protein and the Pulmonary Embolism Severity Index in patients with acute pulmonary embolism in the emergency department Heart-type fatty acid-binding protein (h-FABP), sensitive troponins, natriuretic peptides, and clinical scores such as the Pulmonary Embolism Severity Index (PESI) are candidates for risk stratification of patients with acute pulmonary embolism (PE). The aim was to compare their respective prognostic values to predict

Full Text available with Trip Pro

2015 EvidenceUpdates

127. Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy?

Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? BestBets: Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? Report By: Hyun Choi - CT3 Search checked by Christopher Morgan - Institution: Central Manchester University Hospitals NHS Foundation Trust, University Of Manchester Date Submitted: 27th November 2010 (...) Date Completed: 5th January 2015 Last Modified: 5th January 2015 Status: Green (complete) Three Part Question [In an asymptomatic patient with small subsegmental pulmonary embolism] does [anticoagulation therapy or no treatment] lead to [reduced mortality and a lower rate of recurrent venous thromboembolism?] Clinical Scenario A 49 year old male, who was previously fit and well, attended the Emergency Department as a trauma patient after being involved in a road traffic collision. He underwent

2015 BestBETS

128. Current antipsychotic drug treatment may increase the risk of pulmonary embolism

Current antipsychotic drug treatment may increase the risk of pulmonary embolism Current antipsychotic drug treatment may increase the risk of pulmonary embolism | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current antipsychotic drug treatment may increase the risk of pulmonary embolism Article Text Causes and risk factors Current antipsychotic drug treatment may increase the risk of pulmonary embolism Marie Tournier Statistics

2015 Evidence-Based Mental Health

129. Can Computed Tomography?Assessed Right-Sided Ventricular Dysfunction Predict Mortality in Hemodynamically Stable Pulmonary Embolism?

Can Computed Tomography?Assessed Right-Sided Ventricular Dysfunction Predict Mortality in Hemodynamically Stable Pulmonary Embolism? Systematic Review Snapshot TAKE-HOME MESSAGE Right-sided ventricular dysfunction assessed by computed tomography (CT) isassociatedwithall-causeshort-termmortalityandmorestronglyassociatedwith mortality caused by pulmonary embolism. Can Computed Tomography–Assessed Right-Sided Ventricular Dysfunction Predict Mortality in Hemodynamically Stable Pulmonary Embolism (...) only hemodynamically stable patients. Five of the included studies were retrospective and 5 were pro- spectively designed. Nine studies de?ned evidence of right-sided ventricular dysfunction similarly, using right-ventricular or left- ventricular-diameter ratios of 0.9 to 1.0, and 1 study de?ned right- sided ventricular dysfunction as a right ventricular/left ventricu- lar ratio greater than 1.5. Only 3 studies reported pulmonary embolism–related mortality as an outcome. Overall mortality Pooled

2015 Annals of Emergency Medicine Systematic Review Snapshots

130. Randomised controlled trial: An IVC filter and anticoagulation for 3?months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism

Randomised controlled trial: An IVC filter and anticoagulation for 3?months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism An IVC filter and anticoagulation for 3 months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism Article Text Therapeutics/Prevention Randomised controlled trial An IVC filter and anticoagulation for 3 months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism Eric K Hoffer Statistics from Altmetric.com Commentary on: Mismetti P , Laporte S , Pellerin O , et al ; PREPIC2 Study Group. Effect of a retrievable inferior vena

2015 Evidence-Based Medicine (Requires free registration)

131. Rapid Quantitative D-dimer to Exclude Pulmonary Embolism: A Prospective Cohort Management Study (PubMed)

Rapid Quantitative D-dimer to Exclude Pulmonary Embolism: A Prospective Cohort Management Study ESSENTIALS: It is not known if D-dimer testing alone can safely exclude pulmonary embolism (PE). We studied the safety of using a quantitative latex agglutination D-dimer to exclude PE in 808 patients. 52% of patients with suspected PE had a negative D-dimer test and were followed for 3 months. The negative predictive value of D-dimer testing alone was 99.8%, suggesting it may safely exclude (...) PE.Strategies are needed to exclude pulmonary embolism (PE) efficiently without the need for imaging tests. Although validated rules for clinical probability assessment can be combined with D-dimer testing to safely exclude PE, the rules can be complicated or partially subjective, which limits their use.To determine if PE can be safely excluded in patients with a negative D-dimer without incorporating clinical probability assessment.We enrolled consecutive outpatients and inpatients with suspected PE from

Full Text available with Trip Pro

2015 EvidenceUpdates

132. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians

Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians Evaluation of Patients With Suspected Acute Pulmonary Embolism | Annals of Internal Medicine | American College of Physicians '); } '); })(); Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN (...) IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 3 November 2015 Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians Free Ali S. Raja, MD; Jeffrey O. Greenberg, MD; Amir Qaseem, MD, PhD, MHA; Thomas D. Denberg, MD, PhD; Nick Fitterman, MD; Jeremiah D. Schuur, MD, MHS; for the Clinical Guidelines Committee

Full Text available with Trip Pro

2015 American College of Physicians

133. Inferior Vena Cava Filters for Prevention of Pulmonary Embolism

Inferior Vena Cava Filters for Prevention of Pulmonary Embolism 1 COVERAGE GUIDANCE: INFERIOR VENA CAVA FILTERS FOR PREVENTION OF PULMONARY EMBOLI Approved March 12, 2015 HERC COVERAGE GUIDANCE Inferior vena cava (IVC) filters are recommended for coverage in: ? Patients with active deep vein thrombosis/pulmonary embolism (DVT/PE) for which anticoagulation is contraindicated (strong recommendation) ? Some hospitalized patients with trauma* (weak recommendation) Retrieval of removable IVC filters (...) -populations-130607.pdf Sobieraj, D.M., Coleman, C.I., Tongbram, V., Lee, S., Colby, J., Chen, W.T., et al. (2012). Venous thromboembolism in orthopedic surgery. Rockville, MD: AHRQ. Retrieved on October 2, 2014, from http://effectivehealthcare.ahrq.gov/ehc/products/186/992/CER- 49_VTE_20120313.pdf Young, T., Tang, H., & Hughes, R. (2010). Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev, 2(2). DOI: 10.1002/14651858.CD006212.pub4 Additional sources Decousus, H

2015 Oregon Health Evidence Review Commission

134. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism Dabigatr Dabigatran ete an etexilate for the treatment xilate for the treatment and secondary pre and secondary prev vention of deep v ention of deep vein ein thrombosis and/or pulmonary embolism thrombosis and/or pulmonary embolism T echnology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327 © NICE 2018. All rights reserved. Subject to Notice of rights (...) and/or pulmonary embolism (TA327) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 48Contents Contents 1 Guidance 4 2 The technology 5 3 The company's submission 6 T able 1 Summary of adverse events in the RE-COVER trials, RE-MEDY and RE-SONATE 8 4 Consideration of the evidence 24 Clinical effectiveness 26 Cost effectiveness 29 Summary of Appraisal Committee's key conclusions 33 5 Implementation 40 6 Review of guidance 41

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

135. Accuracy of the Wells Clinical Prediction Rule for Pulmonary Embolism in Older Ambulatory Adults (PubMed)

Accuracy of the Wells Clinical Prediction Rule for Pulmonary Embolism in Older Ambulatory Adults To determine whether the Wells clinical prediction rule for pulmonary embolism (PE), which produces a point score based on clinical features and the likelihood of diagnoses other than PE, combined with normal D-dimer testing can be used to exclude PE in older unhospitalized adults.Prospective cohort study.Primary care and nursing homes.Older adults (≥60) clinically suspected of having a PE (N = 294 (...) , mean age 76, 44% residing in a nursing home).The presence of PE was confirmed using a composite reference standard including computed tomography and 3-month follow-up. The proportion of individuals with an unlikely risk of PE was calculated according to the Wells rule (≤4 points) plus a normal qualitative point-of-care D-dimer test (efficiency) and the presence of symptomatic PE during 3 months of follow-up within these patients (failure rate).Pulmonary embolism occurred in 83 participants (28

2014 EvidenceUpdates

136. Outpatient versus inpatient treatment for acute pulmonary embolism. (PubMed)

Outpatient versus inpatient treatment for acute pulmonary embolism. Pulmonary embolism (PE) is a common life-threatening cardiovascular condition, with an incidence of 23 to 69 new cases per 100,000 people per year. Outpatient treatment instead of traditional inpatient treatment in selected non-high-risk patients with acute PE might provide several advantages, such as reduction of hospitalizations, substantial cost saving and an improvement in health-related quality of life.To compare

2014 Cochrane

137. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study (PubMed)

Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study Patients with polymyositis (PM) and dermatomyositis (DM) may have an increased risk of venous thromboembolism (VTE); however, no general population data are available to date. The purpose of this study was to estimate the future risk and time trends of new VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)) in individuals with incident PM/DM

Full Text available with Trip Pro

2014 EvidenceUpdates

138. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism (PubMed)

Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism The optimal N-terminal pro-brain natriuretic peptide (NT-proBNP) cut-off value for risk stratification of pulmonary embolism remains controversial. In this study we validated and compared different proposed NT-proBNP cut-off values in 688 normotensive patients with pulmonary embolism. During the first 30 days, 28 (4.1%) patients reached the primary outcome (pulmonary embolism (...) a prognostic impact on top of that of the simplified Pulmonary Embolism Severity Index and right ventricular dysfunction on echocardiography (OR 4.27 (95% CI 1.22-15.01); p=0.024, c-index 0.741). The use of a stepwise approach based on the simplified Pulmonary Embolism Severity Index, NT-proBNP ≥ 600 pg·mL(-1) and echocardiography helped optimise risk assessment. Our findings confirm the prognostic value of NT-proBNP and suggest that a cut-off value of 600 pg·mL(-1) is most appropriate for risk

Full Text available with Trip Pro

2014 EvidenceUpdates

139. PE rule-out criteria (PERC) for excluding pulmonary embolism.

PE rule-out criteria (PERC) for excluding pulmonary embolism. BestBets: PE rule-out criteria (PERC) for excluding pulmonary embolism. PE rule-out criteria (PERC) for excluding pulmonary embolism. Report By: Dr Johan Victor Rehnberg - ACCS (Emergency Medicine) CT2 Search checked by Dr Anna Vondy - Specialist Registrar (Emergency Medicine) Institution: Royal Liverpool University Hospital, Liverpool, UK Date Submitted: 7th November 2012 Date Completed: 26th February 2014 Last Modified: 26th (...) help exclude PE without the need for D-dimer testing. Search Strategy The Cochrane Library issue 10 of 12 October 2013: ‘(Pulmonary Embolism’ [MeSH; explode all trees] AND ‘Diagnosis’ [MeSH term; explode all trees]) OR (‘PERC’ OR ‘PE rule out criteria’ OR ‘Pulmonary embolism rule out criteria’ OR ‘PE rule-out criteria’ OR ‘Pulmonary embolism rule-out criteria’ OR ‘PE rule out’ OR ‘Pulmonary embolism rule out’ OR ‘PE rule-out’ OR ‘Pulmonary embolism rule-out’). Medline/EMBASE from 2004 to 29th

2014 BestBETS

140. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism

Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism (...) URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Humans; Morpholines; Pulmonary Embolism; Thiophenes Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000739 Date abstract record

2014 Health Technology Assessment (HTA) Database.